PT-141

PT-141 Injection: Buying Guide for HSDD

Our Price $59.99 Price Match Promise Found a lower price? We'll match it.
x
Secure Encrypted Payments

PT-141 is a prescription treatment for hypoactive sexual desire disorder in certain adults. This guide explains how it works, who it may suit, and safe use. We offer US shipping from Canada with options for PT-141 without insurance.

What PT-141 Is and How It Works

Vyleesi® is the FDA-approved brand name for bremelanotide, the active ingredient in this medicine. It is an on-demand therapy given as a subcutaneous injection before anticipated sexual activity. The treatment is a melanocortin receptor agonist that activates pathways in the brain tied to sexual desire and arousal. It does not treat pain, relationship problems, or other causes of low interest unrelated to HSDD. Border Free Health connects U.S. patients with licensed Canadian partner pharmacies; prescriptions are verified with prescribers before dispensing.

This therapy is distinct from hormonal products. It may raise blood pressure for a short time after use and can cause nausea. Review the official prescribing information and speak with a clinician for personalized guidance.

Who It’s For

This treatment is indicated for premenopausal adults with acquired, generalized hypoactive sexual desire disorder. It is not for sexual difficulties due to relationship issues, medical or psychiatric conditions, or effects of other drugs. It has not been established for postmenopausal adults or adolescents. Use the Hypoactive Sexual Desire Disorder resource to learn more about the condition. For broader wellness topics, see Womens Health.

Some patients ask about PT-141 for women as an on-demand option. A prescriber will confirm if the diagnosis fits and whether this therapy is appropriate. Those with uncontrolled hypertension or cardiovascular disease may need a different approach.

Dosage and Usage

Follow your prescriber’s instructions and the product label. The usual single dose is administered subcutaneously at least 45 minutes before anticipated sexual activity. Do not use more than one dose within 24 hours. Do not exceed eight doses in a month. Choose the abdomen or thigh for injection unless your prescriber advises otherwise. Read the patient instructions before first use, and practice with a trainer or guidance if offered.

If you are reviewing PT-141 dosage details, remember that individual needs vary. Rotate injection sites to reduce local reactions. Allow the device to reach room temperature as directed before use. If you experience severe nausea, contact your healthcare professional for advice.

For additional context on getting prescription medicines online, see our article Buy Online Guide.

Strengths and Forms

The approved presentation is a single-dose, prefilled autoinjector designed for subcutaneous administration. A typical single-use device contains a fixed dose appropriate for one on-demand injection. Availability can vary by partner pharmacy and jurisdiction. Some clinics discuss PT-141 nasal spray in general conversation; note that the FDA-approved labeling in the United States is for the subcutaneous form.

Product listings can change. If a particular device is out of stock, a prescriber may recommend an alternative. Explore related classes under Peptides to understand this therapy family.

Missed Dose and Timing

This is used on demand, not on a fixed daily schedule. If you planned to use a dose and the timing passed, skip it. Do not take two doses close together. Space doses at least 24 hours apart. If you miss the window for a planned occasion, wait for the next suitable time as advised by your prescriber.

Storage and Travel Basics

Store the device according to the manufacturer’s label, in its original packaging, and away from excess heat, moisture, and direct light. Keep out of the reach of children and pets. Do not freeze. When traveling, carry the device in your hand luggage along with a copy of your prescription. A travel letter from your prescriber can help at security checkpoints. Use a protective case to prevent damage to the autoinjector. Our pharmacies use temperature-controlled handling when required.

Dispose of used devices safely after each dose. Never share injection devices. Check the expiration date on the carton before use and do not use if the package is damaged.

Pen Handling and Sharps Disposal

Wash and dry hands. Select the abdomen or thigh. Clean the skin with an alcohol swab and allow to dry. Remove the device cap per the instructions. Place the injector against the skin at a right angle and activate as directed. Hold in place until the indicator shows the dose is complete. After use, place the device directly into an FDA-cleared sharps container. If you do not have one, use a heavy-duty, puncture-resistant container with a secure lid. Follow local rules for sharps disposal.

Benefits

This treatment is used on demand, so there is no daily pill burden. It can be self-administered at home. A single-use device supports consistent dosing. It targets central pathways associated with desire rather than affecting estrogen levels. For partner-related erection concerns, explore Erectile Dysfunction education and options. People often consider overall relationship and communication strategies alongside medical therapy.

Patients researching PT-141 benefits should also consider potential adverse effects, interactions, and whether the diagnosis is appropriate. Discuss goals and concerns with a clinician to set realistic expectations.

Side Effects and Safety

  • Nausea, sometimes severe, especially after early doses
  • Flushing or warmth
  • Headache
  • Vomiting
  • Injection site reactions like redness or pain
  • Transient increase in blood pressure with possible heart rate drop
  • Fatigue or dizziness

Serious risks are uncommon but can include significant nausea or hypertensive responses that require medical attention. Do not use if you have uncontrolled hypertension or certain cardiovascular conditions unless a prescriber confirms safety. This medicine can delay gastric emptying and may affect absorption of oral medications. If you take oral drugs that require precise levels, ask your prescriber how to time them.

If you want a deeper dive into managing dermatologic or topical side effects for a partner’s ED gel, see Eroxon Side Effects for general education.

People reviewing PT-141 side effects should also read the official label for the most complete list and warnings.

Drug Interactions and Cautions

This treatment may reduce exposure to some oral medications by slowing gastric emptying. Caution is advised with oral drugs that need exact blood levels, including those with narrow therapeutic index. Consult your prescriber before combining it with naltrexone-containing products. Avoid alcohol-related risk behaviors if you experience dizziness or nausea. Not recommended during pregnancy or while breastfeeding unless a clinician determines the benefit outweighs the risk. It is not indicated for pediatric use. For men’s sexual health topics, see Mens Health resources.

What to Expect Over Time

On-demand use means effects may vary by occasion. Some individuals choose to reassess after several attempts to determine whether benefits outweigh side effects. Adherence to spacing rules helps reduce risks. Keep a simple log of timing, dose use, and how you felt after each dose. Share those notes with your prescriber during follow-up. If severe nausea or flushing occurs, contact your clinician before using another dose.

Compare With Alternatives

For HSDD, a daily oral option is flibanserin, offered as Addyi. It is taken every night and has different precautions, including alcohol restrictions. For partners with erection concerns rather than desire issues, a phosphodiesterase inhibitor like Vardenafil addresses erectile function, not HSDD. Compare mechanisms, schedules, and cautions with your prescriber to choose the most suitable path.

Pricing and Access

Canadian pharmacy pricing can offer meaningful savings compared with typical U.S. cash-pay costs. Review PT-141 price details on this page to see current options and formats. We support secure checkout and verified prescriptions. Fulfilment Ships from Canada to US, with transparent tracking. If you are exploring cost-saving strategies, consider speaking with your prescriber about multi-month fills if appropriate.

For related education on ED treatments that sometimes affect household planning, review Sildenafil Vs Tadalafil, Viagra And Cialis, and How Eroxon Works.

Availability and Substitutions

Supply can fluctuate. If a specific presentation is not available, your prescriber may recommend an alternative or a different schedule. We do not promise restock dates. Keep your prescription current so you can proceed quickly when inventory is available.

Patient Suitability and Cost-Saving Tips

Candidates include premenopausal adults with acquired, generalized HSDD confirmed by a clinician. People with uncontrolled hypertension, cardiovascular disease, or significant gastrointestinal disorders may not be good candidates. Always review your full medication list with a healthcare professional. To manage costs, consider longer dispensing intervals when safe, set refill reminders, and align reorders to planned travel so you can store your medicine properly. Explore broader condition pages like Womens Health and Peptides to understand therapy context.

Questions to Ask Your Clinician

  • Is my diagnosis consistent with acquired, generalized HSDD?
  • How should I space doses to reduce side effects?
  • Which of my oral medicines could be affected by delayed gastric emptying?
  • What signs mean I should pause and contact you?
  • How long should I try on-demand doses before reassessing?
  • Would a daily alternative better fit my goals and medical history?

Authoritative Sources

FDA Prescribing Information

DailyMed Drug Label

Manufacturer Product Site

Ready to proceed? Place your order with US delivery from Canada and prompt, express shipping. This information is educational and not a substitute for professional medical advice.

Express Shipping - from $25.00

Shipping with this method takes 3-5 days

Prices:
  • Dry-Packed Products $25.00
  • Cold-Packed Products $35.00
Shipping Countries:
  • United States (all contiguous states**)
  • Worldwide (excludes some countries***)

Standard Shipping - $15.00

Shipping with this method takes 5-10 days

Prices:
  • Dry-Packed Products $15.00
  • Not available for Cold-Packed products
Shipping Countries:
  • United States (all contiguous states**)
  • Worldwide (excludes some countries***)

Rewards Program

Earn points on birthdays, product orders, reviews, friend referrals, and more! Enjoy your medication at unparalleled discounts while reaping rewards for every step you take with us.

You can read more about rewards here.

POINT VALUE

100 points
1 USD

How to earn points

  • 1Register and/or Login
    Create an account and start earning.
  • 2Earn Rewards
    Earn points every time you shop or perform certain actions.
  • 3Redeem
    Redeem points for exclusive discounts.

How to book an appointment

  • 1Register and/or Login
    Create Begin by completing a profile or log into your existing account. This step ensures we have the necessary information to provide you with a service that's tailored to your needs. account and start earning.
  • 2Book an appointment
    Scheduling an appointment with our online booking system is easy. Pick a day and time that suits you. You’ll receive an immediate confirmation, without the wait.
  • 3Meet one of our doctors
    Discuss your concerns and symptoms and receive a thorough diagnosis from one of our licensed doctors during a confidential video appointment.
  • 4Get your prescription
    If you've been prescribed medication, your Rx is sent directly to one of our licensed pharmacies and delivered right to your door.

Get Started

To book an online doctor appointment, register for an account or login. After doing so, you can book your visit on this page.

You Might Also Like

GHK-Cu

$47.49

  • In Stock
  • Express Shipping
Our Price $47.49
Select options This product has multiple variants. The options may be chosen on the product page
DSIP

$35.14

  • In Stock
  • Express Shipping
Our Price $35.14
Select options This product has multiple variants. The options may be chosen on the product page
Ipamorelin

$47.49

  • In Stock
  • Express Shipping
Our Price $47.49
Select options This product has multiple variants. The options may be chosen on the product page
NAD+

$66.49

  • In Stock
  • Express Shipping
Our Price $66.49
Select options This product has multiple variants. The options may be chosen on the product page

Peptide Screening Form

Patient Information

Please provide your basic demographic information.

Type your date of birth in MM/DD/YYYY format.

Peptides of Interest

Peptides of Interest

Select the peptides you are interested in or have been recommended.

Medical History & Screening

Medical History & Screening

Please indicate if any of the following apply to you. Red flag alerts will appear if a condition contraindicates any of the available peptide therapies.

Contraindicated for CJC-1295: Growth hormone-releasing peptides like CJC-1295 are contraindicated in patients with active cancer because they may promote cell proliferation and tumor growth.

Contraindicated for Ipamorelin: Ipamorelin stimulates growth hormone release, which may promote tumor growth and cell proliferation in active cancers.

Contraindicated for Sermorelin: Sermorelin increases growth hormone production, which may stimulate growth of existing tumors.

Contraindicated for BPC-157: BPC-157 promotes angiogenesis (new blood vessel formation), which could support tumor growth and metastasis in active cancers.

Contraindicated for AOD-9604: Although AOD-9604 is a modified GH fragment, it may still interact with growth-related pathways in patients with active malignancies.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 promotes cell migration and angiogenesis, which may facilitate tumor growth and metastasis in active cancers.

Contraindicated for GHK-Cu: GHK-Cu promotes angiogenesis and tissue remodeling, which may support tumor growth in patients with active cancer.

Contraindicated for Epithalon (Epitalon): Epithalon stimulates telomerase activity. Cancer cells exploit telomerase to achieve immortality, potentially accelerating tumor growth.

Contraindicated for Semax: Semax has neurotrophic properties that promote cell growth, which may be concerning in patients with active malignancies.

Contraindicated for MOTS-c: MOTS-c influences cellular metabolism and AMPK pathways. Effects on cancer cell metabolism are not fully understood.

Contraindicated for Tesamorelin: Tesamorelin stimulates growth hormone release, which may promote tumor growth in patients with active malignancies.

Contraindicated for Hexarelin: Hexarelin stimulates growth hormone release, which may promote tumor growth and cell proliferation.

Contraindicated for GHRP-6: GHRP-6 stimulates growth hormone release, which may promote tumor growth in active cancers.

Contraindicated for GHRP-2: GHRP-2 stimulates growth hormone release, which may promote tumor growth in active malignancies.

Contraindicated for Melanotan II: Melanotan II stimulates melanocyte activity. In patients with skin cancers, particularly melanoma, it may accelerate disease progression.

Contraindicated for Dihexa: Dihexa activates hepatocyte growth factor (HGF) pathways, which can promote tumor growth and metastasis.

Contraindicated for Kisspeptin-10: Kisspeptin-10 influences reproductive hormone pathways. Hormone-sensitive cancers may be affected by altered GnRH and gonadotropin levels.

Contraindicated for Humanin: Humanin has anti-apoptotic properties that may protect cancer cells from programmed cell death, potentially supporting tumor survival.

Contraindicated for Retatrutide: Retatrutide acts on multiple metabolic pathways including GLP-1 and GIP receptors. Its effects on cell proliferation in patients with active malignancies have not been fully characterized.

Contraindicated for CJC-1295: CJC-1295 stimulates growth hormone release, which can increase IGF-1 levels. Elevated IGF-1 has been associated with cancer recurrence.

Contraindicated for Ipamorelin: The growth hormone and IGF-1 elevation from Ipamorelin may increase the risk of cancer recurrence.

Contraindicated for Sermorelin: Growth hormone stimulation from Sermorelin elevates IGF-1, which has been linked to increased cancer recurrence risk.

Contraindicated for BPC-157: The pro-angiogenic properties of BPC-157 may potentially support recurrence by promoting blood vessel growth that could feed dormant cancer cells.

Contraindicated for TB-500 (Thymosin Beta-4): The pro-angiogenic and cell-migration properties of TB-500 may increase the risk of cancer recurrence.

Contraindicated for Epithalon (Epitalon): Telomerase activation from Epithalon may increase the risk of cancer recurrence by supporting abnormal cell survival.

Contraindicated for Tesamorelin: Growth hormone and IGF-1 elevation from Tesamorelin may increase risk of cancer recurrence.

Contraindicated for Hexarelin: Elevated growth hormone and IGF-1 from Hexarelin may increase risk of cancer recurrence.

Contraindicated for GHRP-6: Growth hormone and IGF-1 elevation from GHRP-6 may increase risk of cancer recurrence.

Contraindicated for GHRP-2: Elevated IGF-1 from GHRP-2-stimulated growth hormone may increase cancer recurrence risk.

Contraindicated for Melanotan II: Melanocortin stimulation from Melanotan II may increase melanoma recurrence risk in patients with skin cancer history.

Contraindicated for Dihexa: HGF pathway activation from Dihexa may increase cancer recurrence risk through pro-growth signaling.

Contraindicated for Humanin: The cytoprotective effects of Humanin may increase cancer recurrence risk by inhibiting apoptosis in dormant cancer cells.

Contraindicated for Retatrutide: GLP-1 receptor agonists have been linked to thyroid C-cell tumors in animal studies. Retatrutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.

Contraindicated for Retatrutide: Retatrutide is contraindicated in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) due to the risk of medullary thyroid carcinoma associated with GLP-1 receptor agonists.

Contraindicated for CJC-1295: CJC-1295 has not been studied in pregnancy and may affect fetal development through altered growth hormone levels.

Contraindicated for Ipamorelin: Ipamorelin has not been studied in pregnancy. Altered growth hormone levels may impact fetal development.

Contraindicated for Sermorelin: Sermorelin is not approved for use during pregnancy due to potential effects on fetal growth and development.

Contraindicated for BPC-157: BPC-157 has not been adequately studied in human pregnancy. Its tissue-modulating effects may pose risks to fetal development.

Contraindicated for Thymosin Alpha-1: Immune modulation during pregnancy may disrupt the delicate immune tolerance required for fetal development.

Contraindicated for PT-141: PT-141 is contraindicated in pregnancy as melanocortin receptor activation may affect fetal development.

Contraindicated for AOD-9604: AOD-9604 has not been studied in pregnancy. Its effects on fetal metabolism are unknown.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 has not been studied in pregnancy. Its tissue-remodeling effects may pose risks to fetal development.

Contraindicated for GHK-Cu: GHK-Cu has not been studied in pregnancy. Copper peptide effects on fetal development are unknown.

Contraindicated for Epithalon (Epitalon): Epithalon has not been studied in pregnancy. Effects on fetal cellular development are unknown.

Contraindicated for Selank: Selank has not been studied in pregnancy. Its neuroactive effects may impact fetal brain development.

Contraindicated for Semax: Semax has not been studied in pregnancy. Its neuroactive and hormonal effects may affect fetal development.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): DSIP has not been studied in pregnancy. Its neuroendocrine effects may impact fetal development.

Contraindicated for MOTS-c: MOTS-c has not been studied in pregnancy. Its metabolic effects may impact fetal development.

Contraindicated for Tesamorelin: Tesamorelin is contraindicated in pregnancy due to potential effects on fetal growth from altered growth hormone levels.

Contraindicated for Hexarelin: Hexarelin has not been studied in pregnancy. Altered growth hormone levels may impact fetal development.

Contraindicated for GHRP-6: GHRP-6 has not been studied in pregnancy. Growth hormone modulation may affect fetal development.

Contraindicated for GHRP-2: GHRP-2 has not been studied in pregnancy. Its effects on fetal growth and development are unknown.

Contraindicated for Melanotan II: Melanotan II is contraindicated in pregnancy due to unknown effects on fetal development from melanocortin receptor activation.

Contraindicated for LL-37: LL-37 has not been studied in pregnancy. Immune modulation may disrupt maternal-fetal immune tolerance.

Contraindicated for KPV: KPV has not been studied in pregnancy. Its immunomodulatory effects may impact fetal development.

Contraindicated for Dihexa: Dihexa has not been studied in pregnancy. Its neurotrophic and growth factor effects may impact fetal development.

Contraindicated for 5-Amino-1MQ: 5-Amino-1MQ has not been studied in pregnancy. Its metabolic enzyme inhibition may affect fetal development.

Contraindicated for SS-31 (Elamipretide): SS-31 has not been studied in pregnancy. Its effects on mitochondrial function in developing tissues are unknown.

Contraindicated for PE-22-28: PE-22-28 has not been studied in pregnancy. Its neurogenic effects may impact fetal brain development.

Contraindicated for Kisspeptin-10: Kisspeptin-10 directly affects reproductive hormones and GnRH signaling. Use during pregnancy may disrupt hormonal balance critical for fetal development.

Contraindicated for Humanin: Humanin has not been studied in pregnancy. Its effects on fetal cellular development and apoptosis pathways are unknown.

Contraindicated for KLOW: KLOW has not been studied in pregnancy. Effects on fetal development are unknown.

Contraindicated for GLOW: GLOW has not been studied in pregnancy. Effects on fetal development are unknown.

Contraindicated for Retatrutide: Retatrutide has not been studied in pregnancy. GLP-1 receptor agonists may affect fetal development and maternal glucose regulation.

Contraindicated for CJC-1295: Safety of CJC-1295 during breastfeeding has not been established. Growth hormone modulation could affect lactation.

Contraindicated for BPC-157: Insufficient safety data exists for BPC-157 use during breastfeeding.

Contraindicated for PT-141: Safety of PT-141 during breastfeeding has not been established.

Contraindicated for AOD-9604: Insufficient safety data for AOD-9604 during breastfeeding.

Contraindicated for Selank: Safety of Selank during breastfeeding has not been established. Neuroactive peptides may pass into breast milk.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): Safety of DSIP during breastfeeding has not been established.

Contraindicated for KPV: Safety of KPV during breastfeeding has not been established.

Contraindicated for 5-Amino-1MQ: Safety of 5-Amino-1MQ during breastfeeding has not been established.

Contraindicated for PE-22-28: Safety of PE-22-28 during breastfeeding has not been established. Neuroactive peptides may pass into breast milk.

Contraindicated for Kisspeptin-10: Kisspeptin-10 modulates reproductive hormones, which may affect lactation and hormonal balance during breastfeeding.

Contraindicated for KLOW: Safety of KLOW during breastfeeding has not been established.

Contraindicated for GLOW: Safety of GLOW during breastfeeding has not been established.

Contraindicated for Retatrutide: Safety of Retatrutide during breastfeeding has not been established. It is unknown whether the peptide is excreted in breast milk.

Contraindicated for CJC-1295: Growth hormone elevation from CJC-1295 can worsen diabetic retinopathy by promoting abnormal blood vessel growth in the retina.

Contraindicated for Ipamorelin: Elevated growth hormone from Ipamorelin can accelerate retinal neovascularization in diabetic retinopathy.

Contraindicated for GHRP-6: Elevated growth hormone from GHRP-6 can worsen diabetic retinopathy by promoting abnormal blood vessel growth.

Contraindicated for GHRP-2: Growth hormone elevation from GHRP-2 can accelerate retinal neovascularization in diabetic retinopathy.

Contraindicated for Retatrutide: Rapid improvement in glycemic control from Retatrutide may temporarily worsen diabetic retinopathy. Close ophthalmologic monitoring is recommended.

Contraindicated for CJC-1295: Growth hormone-releasing peptides can elevate intracranial pressure, worsening existing intracranial hypertension.

Contraindicated for Sermorelin: Growth hormone elevation from Sermorelin can increase intracranial pressure.

Contraindicated for Tesamorelin: Growth hormone elevation from Tesamorelin can increase intracranial pressure.

Contraindicated for CJC-1295: CJC-1295 acts on the pituitary gland. Existing pituitary disorders may lead to unpredictable or dangerous hormone responses.

Contraindicated for Ipamorelin: Ipamorelin directly stimulates the pituitary gland. Pre-existing pituitary conditions may result in adverse hormonal responses.

Contraindicated for Sermorelin: Sermorelin requires a functioning pituitary gland. Pituitary disorders may prevent proper response or cause adverse effects.

Contraindicated for DSIP (Delta Sleep-Inducing Peptide): DSIP affects neuroendocrine signaling involving the pituitary gland. Pre-existing pituitary conditions may lead to unpredictable effects.

Contraindicated for Tesamorelin: Tesamorelin acts directly on the pituitary gland. Pre-existing pituitary disorders may cause unpredictable hormonal responses.

Contraindicated for Hexarelin: Hexarelin acts on the pituitary gland. Pre-existing pituitary conditions may result in adverse hormonal responses.

Contraindicated for GHRP-6: GHRP-6 acts directly on the pituitary gland. Pre-existing disorders may cause adverse hormonal effects.

Contraindicated for GHRP-2: GHRP-2 directly stimulates the pituitary gland. Pre-existing pituitary disorders may cause unpredictable responses.

Contraindicated for Kisspeptin-10: Kisspeptin-10 stimulates the hypothalamic-pituitary axis. Pre-existing pituitary disorders may lead to unpredictable hormonal responses.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 stimulates T-cell activity and immune response. In patients with autoimmune conditions, this can trigger disease flares.

Contraindicated for Epithalon (Epitalon): Epithalon may modulate immune function through its effects on the pineal gland, potentially exacerbating autoimmune conditions.

Contraindicated for Melanotan II: Melanotan II modulates immune function through melanocortin receptors, potentially exacerbating autoimmune conditions.

Contraindicated for LL-37: LL-37 is a potent immune activator. In autoimmune conditions, it may trigger inflammatory flares and worsen disease activity.

Contraindicated for KLOW: Peptide blends may modulate immune function. Patients with autoimmune conditions should consult their provider before use.

Contraindicated for GLOW: Peptide blends may modulate immune function. Patients with autoimmune conditions should consult their provider before use.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 enhances immune function, which directly counteracts immunosuppressive therapy required to prevent organ rejection.

Contraindicated for LL-37: LL-37 enhances immune function, which may counteract immunosuppressive therapy in transplant recipients.

Contraindicated for PT-141: PT-141 affects blood pressure and cardiovascular function. Patients with heart disease face increased risk of adverse cardiac events.

Contraindicated for Hexarelin: Hexarelin has been shown to affect cardiac function and cortisol release. Patients with cardiovascular disease should use caution.

Contraindicated for Melanotan II: Melanotan II affects cardiovascular function and can cause nausea and flushing. Heart disease patients should avoid use.

Contraindicated for PT-141: PT-141 can cause transient increases in blood pressure. Uncontrolled hypertension increases the risk of cardiovascular events.

Contraindicated for Semax: Semax can influence blood pressure regulation. Patients with uncontrolled hypertension should use caution.

Contraindicated for Melanotan II: Melanotan II can cause blood pressure fluctuations. Patients with uncontrolled hypertension face increased cardiovascular risk.

Contraindicated for Dihexa: Dihexa may influence cardiovascular function. Patients with uncontrolled hypertension should exercise caution.

Contraindicated for AOD-9604: Patients with severe kidney disease may have impaired clearance of AOD-9604 metabolites.

Contraindicated for MOTS-c: Patients with severe kidney disease may have impaired clearance of MOTS-c metabolites.

Contraindicated for 5-Amino-1MQ: Patients with kidney disease may have impaired clearance of 5-Amino-1MQ metabolites.

Contraindicated for SS-31 (Elamipretide): Patients with severe kidney disease may have impaired clearance of SS-31 and its metabolites.

Contraindicated for Retatrutide: Patients with severe kidney disease may have impaired clearance of Retatrutide. Dose adjustment or avoidance may be necessary.

Contraindicated for GHK-Cu: Copper metabolism is heavily dependent on liver function. Patients with liver disease may accumulate copper to toxic levels.

Contraindicated for 5-Amino-1MQ: 5-Amino-1MQ affects metabolic enzyme pathways. Patients with liver disease may experience altered drug metabolism and increased toxicity risk.

Contraindicated for Retatrutide: Retatrutide is metabolized hepatically. Patients with significant liver impairment may experience altered drug levels and increased risk of adverse effects.

Contraindicated for Retatrutide: GLP-1 receptor agonists, including Retatrutide, have been associated with an increased risk of pancreatitis. Patients with a history of pancreatitis should avoid use.

Contraindicated for BPC-157: BPC-157 affects the nitric oxide system and may influence blood clotting. Patients with clotting disorders should avoid use.

Contraindicated for TB-500 (Thymosin Beta-4): TB-500 can influence blood clotting pathways. Patients with clotting disorders or on anticoagulants should avoid use.

Contraindicated for Selank: Selank is derived from tuftsin, which can influence immune and coagulation pathways. Patients with clotting disorders should use caution.

Contraindicated for SS-31 (Elamipretide): SS-31 has been associated with injection site reactions. Patients with known peptide allergies should be monitored.

Contraindicated for KLOW: Multi-component peptide blends carry increased risk of allergic reactions. Patients with known peptide allergies should be monitored.

Contraindicated for GLOW: Multi-component peptide blends carry increased risk of allergic reactions. Patients with known peptide allergies should be monitored.

Contraindicated for Thymosin Alpha-1: Thymosin Alpha-1 directly opposes immunosuppressive medications, potentially causing dangerous drug interactions.

Contraindicated for LL-37: LL-37 stimulates immune responses, potentially opposing immunosuppressive medications.

Contraindicated for KPV: KPV has anti-inflammatory and immune-modulating effects that may interact with immunosuppressive medications.

Current Medications

List all medications, supplements, and treatments you are currently using.

Additional Notes

Medical Disclaimer

This screening questionnaire is for informational and pre-consultation purposes only. It does not constitute medical advice, diagnosis, or a treatment recommendation.

All peptide therapy protocols must be prescribed and supervised by a licensed healthcare provider. The contraindication information provided here is based on general clinical guidelines and may not reflect every individual’s unique medical circumstances.

Peptide therapies are used off-label in many cases. Results vary by individual. Borderfreehealth.com does not guarantee outcomes from any peptide therapy program.

By submitting this form, you acknowledge that a qualified medical professional will review your responses and determine appropriate treatment options. Do not discontinue any current medications or begin any new treatment based solely on the results of this screening.